On Monday, Nexalin Technology, Inc. (NASDAQ:NXL) announced the publication of a study in the Journal of Alzheimer’s Disease.
The study builds on recent findings from Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).
The new research involved 46 randomly assigned patients receiving either real DIFS or sham treatment for 30 one-hour sessions over three weeks.
Resting-state functional magnetic resonance imaging (rs-fMRI) was used to track changes in brain activity.
Key Findings of the Study Include:
The study indicated no serious side effects reported among participants.
Despite undergoing twice-daily stimulation sessions over three weeks, elderly patients tolerated the treatment well, with only minor sensations such as tingling that resolved quickly.
The company adds that Alzheimer’s disease affects over 50 million people globally, and it is projected to rise to over 113 million by 2050.
Price Action: NXL stock is down 4.37% at $2.19 during the premarket session at last check Monday.
Read Next:
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。